ライフサイエンスコーパス: pneumococcal pneumonia

1 chanism of alveolar macrophage cell death in pneumococcal pneumonia.

2 Pdelta in host defense in community-acquired pneumococcal pneumonia.

3 inflammatory, and noxious stimuli, including pneumococcal pneumonia.

4 challenge) with rhu-pGSN in a mouse model of pneumococcal pneumonia.

5 ssion and aids neutrophil recruitment during pneumococcal pneumonia.

6 T3 activation augmented host defense against pneumococcal pneumonia.

7 s, thus promoting early bacterial killing in pneumococcal pneumonia.

8 showed reduced virulence in a mouse model of pneumococcal pneumonia.

9 improved protection against otitis media and pneumococcal pneumonia.

10 oman presents with severe community-acquired pneumococcal pneumonia.

11 thesis confers resistance to s/s mice during pneumococcal pneumonia.

12 ermine the role of this signaling pathway in pneumococcal pneumonia.

13 rial superinfections, particularly secondary pneumococcal pneumonia.

14 g" with PPV in adults who had recovered from pneumococcal pneumonia.

15 anism underlying the high early mortality of pneumococcal pneumonia.

16 okine is essential to surviving experimental pneumococcal pneumonia.

17 etermine the roles of these cytokines during pneumococcal pneumonia.

18 ystem by a DcR3 analog (DcR3-a) in mice with pneumococcal pneumonia.

19 improves clearance of bacteria in mice with pneumococcal pneumonia.

20 e surface of the pneumococcus in vivo during pneumococcal pneumonia.

21 proposed vaccine antigen can protect against pneumococcal pneumonia.

22 es varied with different case definitions of pneumococcal pneumonia.

23 ced TNF is important for host defense during pneumococcal pneumonia.

24 is factor-alpha (TNF) in the pathogenesis of pneumococcal pneumonia.

25 , including 51 (1.7%) patients with invasive pneumococcal pneumonia.

26 eath during the progression of postinfluenza pneumococcal pneumonia.

27 ae is a necessary step in the development of pneumococcal pneumonia.

28 rriage are likely to result in reductions in pneumococcal pneumonia.

29 A9 protein rescued S100A8 KO mice from fatal pneumococcal pneumonia.

30 unity, making it crucial for the survival of pneumococcal pneumonia.

31 promise as an adjunct therapeutic avenue for pneumococcal pneumonia.

32 tly reported as a useful diagnostic tool for pneumococcal pneumonia.

33 e of blood lytA quantification in diagnosing pneumococcal pneumonia.

34 Welders are at increased risk of pneumococcal pneumonia.

35 gnaling in the liver is important to control pneumococcal pneumonia.

36 ABCD) with the wild type in a mouse model of pneumococcal pneumonia.

37 POSTN as new players in the pathogenesis of pneumococcal pneumonia.

38 ore, liposomes protect mice against invasive pneumococcal pneumonia.

39 the effect of thrombocytopenia during murine pneumococcal pneumonia.

40 evidence for an interaction between RSV and pneumococcal pneumonia.

41 e presentation and outcomes of patients with pneumococcal pneumonia.

42 mice in vitro and in an established model of pneumococcal pneumonia.

43 it did not impact on bacterial loads during pneumococcal pneumonia.

44 njury and inflammatory responses observed in pneumococcal pneumonia.

45 s as a novel therapeutic strategy to control pneumococcal pneumonia.

46 eographic subpopulations at greater risk for pneumococcal pneumonia.

47 swabs may be preferable for the diagnosis of pneumococcal pneumonia.

48 were worse at protecting naive mice against pneumococcal pneumonia.

49 colonization density and, in turn, invasive pneumococcal pneumonia.

50 L1 in macrophages confers protection against pneumococcal pneumonia.

51 with efficient protection against secondary pneumococcal pneumonia.

52 to impaired survival of mice suffering from pneumococcal pneumonia.

53 ologous strain in a murine model of invasive pneumococcal pneumonia.

54 term survival of patients who recovered from pneumococcal pneumonia.

55 4.14 [95% confidence interval, 1.63-10.2]), pneumococcal pneumonia (10.24 [3.48-30.1]), chronic obst

56 eumococcal pneumonia were 58.3% (code 481.0, pneumococcal pneumonia), 20.4% (38.0, streptococcal sept

57 d controls) showed a reduced survival during pneumococcal pneumonia (27% vs 75% among controls; p = 0

58 more sensitive for urine from patients with pneumococcal pneumonia (89.8%) than for urine from patie

59 36, we sought to examine the role of CD36 in pneumococcal pneumonia, a major cause of morbidity and m

60 In pneumococcal pneumonia, a strong local inflammatory cyto

61 usted OR, 1.7; 95% CI, 1.1-2.6) and invasive pneumococcal pneumonia (adjusted OR, 2.3; 95% CI, 1.3-4.

62 t of the programme on rates of all-cause and pneumococcal pneumonia admissions.

63 ds were tested in a mouse model of secondary pneumococcal pneumonia after influenza.

64 za-infected wild-type mice cleared secondary pneumococcal pneumonia after pulmonary administration of

65 R), and urine antigen testing for diagnosing pneumococcal pneumonia among 149 adults with community-a

66 enza was also associated with an increase in pneumococcal pneumonia among children aged 1-2 y (AP: 3.

67 reaction (PCR) on blood in the diagnosis of pneumococcal pneumonia among children from 7 low- and mi

68 redictive values (NPV) of specific codes for pneumococcal pneumonia among hospitalized patients with

69 ion, high colonization density, and invasive pneumococcal pneumonia among patients hospitalized with

70 there was an outbreak of multidrug-resistant pneumococcal pneumonia among the residents of a nursing

71 e, as indicated by 100% survival from lethal pneumococcal pneumonia and 10 000-fold greater efficienc

72 from 14 (27%) of 51 patients with bacteremic pneumococcal pneumonia and 11 (37%) of 30 with nonbacter

73 case was defined as PPV23 serotype-specific pneumococcal pneumonia and a control as non-PPV23 seroty

74 Rate ratios for pneumococcal pneumonia and all-cause pneumonia demonstra

75 model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utiliza

76 garette smoke exposure increases the risk of pneumococcal pneumonia and defines a novel cellular mech

77 able for decreased exposure in patients with pneumococcal pneumonia and E. coli urogenital infections

78 f necrotizing changes in adult patients with pneumococcal pneumonia and examined the severity of infe

79 cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b

80 of IL-22 signaling during a murine model of pneumococcal pneumonia and improvement of bacterial burd

81 vaccine also reduced admissions for invasive pneumococcal pneumonia and non-invasive pneumococcal or

82 Here, we demonstrate that pneumococcal pneumonia and other severe infections incre

83 nd Ply is essential for the establishment of pneumococcal pneumonia and sepsis in a murine model of i

84 Using a sickle cell mouse model of pneumococcal pneumonia and sepsis, administration of hyd

85 ds and improved survival in a mouse model of pneumococcal pneumonia and sepsis.

86 ut PCV13 effectiveness against nonbacteremic pneumococcal pneumonia and the magnitude of potential in

87 rdiac tissue from six adult NHPs with severe pneumococcal pneumonia and three uninfected control anim

88 r their abilities to attenuate the course of pneumococcal pneumonia and to prevent colonization of th

89 ncreased for up to 10 years after documented pneumococcal pneumonia and was greater in proportion to

90 (13.8%) hospitalized for CAP had evidence of pneumococcal pneumonia, and 198 (9.8%) had detection of

91 invasive pneumococcal disease, non-invasive pneumococcal pneumonia, and empyema (all coded by Intern

92 timing of the average seasonal peak of RSV, pneumococcal pneumonia, and pneumococcal septicemia.

93 During pneumococcal pneumonia, antibacterial defense requires t

94 l, for example determining the prevalence of pneumococcal pneumonia as caused by many individual pneu

95 ted with respect to effects on postinfluenza pneumococcal pneumonia as measured by bacterial growth,

96 Pdelta(-/-) mice are relatively resistant to pneumococcal pneumonia, as indicated by delayed and redu

97 and V70 sequence accelerated development of pneumococcal pneumonia, as reflected by increased levels

98 c contributions to the early pathogenesis of pneumococcal pneumonia at different stages of infection

99 gest that IRAK-M impairs host defense during pneumococcal pneumonia at the primary site of infection

100 rotein of 12 kDa impairs host defense during pneumococcal pneumonia at the primary site of infection

101 identified factors associated with invasive pneumococcal pneumonia, bacterial loads, and death.

102 rveillance, all culture-confirmed bacteremic pneumococcal pneumonia (BPP) among adults in Israel.

103 een in 6.6% of a large series of adults with pneumococcal pneumonia but were often overlooked on init

104 airway pneumococcal colonization density and pneumococcal pneumonia, but data in children are limited

105 t an unfavorable role in host defense during pneumococcal pneumonia by a mechanism independent of deg

106 We measured the burden of pneumococcal pneumonia by applying the proportion of pne

107 the lung, thus contributing to resistance to pneumococcal pneumonia by downregulating OXPHOS genes an

108 ibutes to the early pathogenesis of invasive pneumococcal pneumonia by facilitating intrapulmonary ba

109 lammation and bacterial dissemination during pneumococcal pneumonia by promoting host defenses, sugge

110 uring 2007 to 2009 with laboratory-confirmed pneumococcal pneumonia by using monoclonal antibodies an

111 al (NP) swabs distinguish community-acquired pneumococcal pneumonia (CAP) from asymptomatic colonizat

112 cy against invasive pneumococcal disease and pneumococcal pneumonia caused by vaccine serotypes in ol

113 umonia and 11 (37%) of 30 with nonbacteremic pneumococcal pneumonia contained IgG to CPS of the infec

114 certain serotype-specific antibodies against pneumococcal pneumonia could be associated with modulati

115 The seasonality of invasive pneumococcal pneumonia could be due to increased suscept

116 ickle cell mice improved their survival from pneumococcal pneumonia, counteracting the abnormally ele

117 Pneumococcal pneumonia declined from 2.9 to 1.2 cases pe

118 Adult pneumococcal pneumonia declined in western Kenya followi

119 In mice recovered from pneumococcal pneumonia, depletion of PD-L2+ B cells, inc

120 nd bacterial replication in a mouse model of pneumococcal pneumonia, despite being necessary for clea

121 vailable specimen may significantly increase pneumococcal pneumonia diagnoses in adults.

122 of NA inhibition was to limit the extent of pneumococcal pneumonia during early infection.

123 , and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, w

124 p to one-third of patients hospitalized with pneumococcal pneumonia experience major adverse cardiac

125 pital admission, patients with nonbacteremic pneumococcal pneumonia had higher levels of serum anti-p

126 ect 2003-2009, we quantified the increase in pneumococcal pneumonia hospitalization rates above a sea

127 Annual pneumococcal pneumonia hospitalization rates per 100 000

128 ng >700,000 RSV hospitalizations and >16,000 pneumococcal pneumonia hospitalizations in 36 states (19

129 nd 2040, as the population increases by 38%, pneumococcal pneumonia hospitalizations will increase by

130 emic had a significant impact on the rate of pneumococcal pneumonia hospitalizations, with the magnit

131 These results indicate that during pneumococcal pneumonia, IL-10 attenuates the proinflamma

132 During pneumococcal pneumonia, IL-6 down-regulates the activati

133 ctiveness (VE) of PPV23 against vaccine-type pneumococcal pneumonia in a cohort of adults hospitalise

134 ssay has favorable accuracy for diagnosis of pneumococcal pneumonia in adult patients with CAP; this

135 iae is the most common bacterial etiology of pneumococcal pneumonia in adults worldwide.

136 D may become a new standard for detection of pneumococcal pneumonia in adults.

137 h a significant increase in the incidence of pneumococcal pneumonia in children aged <1 y (attributab

138 had poor diagnostic accuracy for diagnosing pneumococcal pneumonia in children in 9 African and Asia

139 lating factor (G-CSF) on the pathogenesis of pneumococcal pneumonia in cirrhosis.

140 y PMNL, G-CSF does not protect against fatal pneumococcal pneumonia in cirrhotic rats.

141 isms in IL33 and IL1RL1 were associated with pneumococcal pneumonia in humans.

142 s limited diagnostic utility for identifying pneumococcal pneumonia in individual children, but may b

143 evaluated the role of AnxA1 and FPR2 during pneumococcal pneumonia in mice.

144 ential benefit of TRAIL-based therapy during pneumococcal pneumonia in mice.

145 The seriousness of pneumococcal pneumonia in mouse models has been shown to

146 and that galectin-3 reduces the severity of pneumococcal pneumonia in part by augmenting neutrophil

147 coccal PCR on blood for diagnosing childhood pneumococcal pneumonia in the 7 low- and middle-income c

148 Accurate diagnosis of pneumococcal pneumonia in the acute-care setting remains

149 e I IFNs controlled RANTES production during pneumococcal pneumonia in vivo.

150 Clinical Modification (ICD-9-CM) to estimate pneumococcal pneumonia incidence and vaccine efficacy.

151 pneumococcal disease, recent measurements of pneumococcal pneumonia incidence are lacking.

152 We examined adult pneumococcal pneumonia incidence before and after PCV in

153 d pneumococcus detected, yielding a baseline pneumococcal pneumonia incidence of 1.12/100 pyo (95% co

154 icantly by clinical presentation: bacteremic pneumococcal pneumonia incidence peaked in late winter,

155 iplied by adjusted ARI incidence to estimate pneumococcal pneumonia incidence.

156 Platelets play a protective role during pneumococcal pneumonia independent of their aggregation.

157 s influenza pandemics, we evaluated invasive pneumococcal pneumonia (IPP) rates during the 2009 influ

158 Weekly rates of invasive pneumococcal pneumonia (IPP) were obtained from the Dani

159 ne the role of IRAK-M in host defense during pneumococcal pneumonia, IRAK-M- deficient and wild-type

160 Pneumococcal pneumonia is a leading cause of death and a

161 Pneumococcal pneumonia is a life-threatening disease wit

162 Diagnosis of pneumococcal pneumonia is complicated by the lack of a d

163 Pneumococcal pneumonia is concentrated among the elderly

164 Hypersusceptibility of welders to pneumococcal pneumonia is in part mediated by the capaci

165 coding data to identify laboratory-confirmed pneumococcal pneumonia is not known.

166 Moreover, pneumococcal pneumonia is the most common opportunistic

167 In a murine model of pneumococcal pneumonia, MARCO(-/-) mice displayed an imp

168 ion antibiotic therapy for severe bacteremic pneumococcal pneumonia may reduce mortality.

169 compared between microbiologically confirmed pneumococcal pneumonia (MCPP) cases, cases confirmed for

170 Microbiologically confirmed pneumococcal pneumonia (MCPP) was confirmed by detection

171 among cases with microbiologically confirmed pneumococcal pneumonia (MCPP), cases without a confirmed

172 een estimated to cause 9.18 million cases of pneumococcal pneumonia, meningitis, and invasive non-pne

173 During pneumococcal pneumonia, Miwi2-deficient mice exhibited i

174 ligation and puncture (CLP) model and in the pneumococcal pneumonia model of sepsis.

175 hu-pGSN improves outcomes in a highly lethal pneumococcal pneumonia model when given after a clinical

176 In 351 cases of pneumococcal pneumonia, necrosis was reported in no (0%)

177 During pneumococcal pneumonia, NF-kappaB proteins translocate t

178 While secondary pneumococcal pneumonia occurs less commonly after corona

179 nia (one [1%] patient in the placebo group), pneumococcal pneumonia (one [1%] in the tralokinumab eve

180 Lung tissue of patients who had died from pneumococcal pneumonia or a nonpulmonary cause was stain

181 neumonia and a control as non-PPV23 serotype pneumococcal pneumonia or nonpneumococcal pneumonia.

182 olysin IgG than did patients with bacteremic pneumococcal pneumonia or uninfected control subjects.

183 V13 on CAP, pleural effusion, and documented pneumococcal pneumonia, particularly cases due to PCV13

184 Determining pneumococcal pneumonia (PP) burden in the elderly popula

185 of PCV13 on a number of clinical aspects of pneumococcal pneumonia (PP) in children has not been rep

186 PP and could be used to improve estimates of pneumococcal pneumonia prevalence in childhood pneumonia

187 Protection against pneumococcal pneumonia relies on successful regulation o

188 Rationale: Pneumococcal pneumonia remains a global health problem.

189 ccess of the pneumococcal conjugate vaccine, pneumococcal pneumonia remains a significant clinical pr

190 Mortality from pneumococcal pneumonia remains high despite antibiotic t

191 all-cause hospitalized pneumonia (ACHP), and pneumococcal pneumonia requiring hospitalization among a

192 oria engendered by the improved prognosis of pneumococcal pneumonia resulting from therapeutic advanc

193 treated male mice show greater resistance to pneumococcal pneumonia, seen as greater bacterial cleara

194 RSV and pneumococcal pneumonia shared a distinctive spatiotempor

195 treated mice died significantly earlier from pneumococcal pneumonia than control mice (p < 0.05).

196 IL-6-/- mice died significantly earlier from pneumococcal pneumonia than did IL-6+/+ mice (P < .05).

197 how neutrophils are recruited to the lung in pneumococcal pneumonia, the ability of pneumococcal comp

198 During pneumococcal pneumonia, the human airway epithelium is e

199 g injury model, but in oleic acid injury and pneumococcal pneumonia, there were no sustained oxygenat

200 We investigated the pathogenesis of pneumococcal pneumonia using clinical specimens collecte

201 mean lytA rtPCR copy number in patients with pneumococcal pneumonia was 6.0 log(10) copies/mL, compar

202 ble analysis among colonized cases, invasive pneumococcal pneumonia was associated with HIV (adjusted

203 ow PCV13 effectiveness against nonbacteremic pneumococcal pneumonia was assumed or when greater child

204 tandard, a composite diagnostic standard for pneumococcal pneumonia was considered positive in South

205 ffects of infection were analyzed in detail, pneumococcal pneumonia was found to alter the expression

206 Because pneumococcal pneumonia was prevalent during previous inf

207 complement properties to the pathogenesis of pneumococcal pneumonia, we compared the in vivo effects

208 contribution of PMNs to host defense against pneumococcal pneumonia, we determined the effect of the

209 tions for patients with laboratory-confirmed pneumococcal pneumonia were 58.3% (code 481.0, pneumococ

210 CAAP and bacteremic pneumococcal pneumonia were strongly reduced (incidence

211 e BALB/c mice, which are highly resistant to pneumococcal pneumonia when infected with other serotype

212 . pneumoniae) causes high early mortality in pneumococcal pneumonia, which is characterized by acute

213 Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion ann

214 Pneumococcal pneumonia with pleural effusion was associa

215 at was associated with recurrent episodes of pneumococcal pneumonia with sepsis and other infections

216 from a 66-year-old resident with bacteremic pneumococcal pneumonia within a Centers for Disease Cont

217 ammation and alveolar barrier dysfunction in pneumococcal pneumonia without compromising host defence